Solid Biosciences (SLDB) news

Payward-Saldo deal seen closing in 2027

The anticipated merger between Payward and Saldo, two prominent players in the digital payments sector, is expected to finalize in 2027, according to recent regulatory filings and internal communications from both companies. The deal, which has been under review by antitrust authorities since early…

Solitron Devices, Inc. announces fiscal 2027 second quarter results

Solitron Devices, Inc. (SODI) has released its fiscal 2027 second-quarter results, marking a period of strategic development for the company. While specific financial figures were not disclosed in the available materials, the firm announced a strategic review process amid record levels of…

Solid Biosciences Inc: RBC initiates coverage with outperform rating; price target $18

RBC Capital Markets has initiated coverage on Solid Biosciences Inc. (NASDAQ: SLDB) with an "Outperform" rating and a price target of $18, reflecting the firm's confidence in the company's clinical progress and strategic direction. Solid Biosciences, a biotechnology firm focused on developing gene…

Solid Biosciences Inc files for offering of up to $200 mln in common stock - SEC filing

Solid Biosciences Inc. (Nasdaq: SLDB) has announced the pricing of an underwritten offering of 35,739,810 shares of its common stock at an offering price of $4.03 per share, with an aggregate gross offering value of approximately $200.0 million before underwriting discounts and other expenses. In…

Solid Biosciences files mixed securities shelf